BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Axiogenesis

NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions

September 18, 2017 By Cade Hildreth (CEO) Leave a Comment

Ncardia, Axiogenesis and Pluriomics

Axiogenesis AG and Pluriomics B.V. are combining forces to form Ncardia, the new global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).

Ncardia, merger of Axiogenesis & PluriomicsFounded in 2001, Axiogenesis AG has Cologne (DE) and Philadelphia (USA) facilities, while Pluriomics B.V. has facilities in Gosselies (BE) and Leiden (NL). By entering into this merger, these European leaders will become the global leader in hiPSC drug discovery and development field, making Ncardia the partner of choice for scientists conducting cardiovascular and neural safety and efficacy projects.

By combining their global client base, the merger of Axiogenesis and Pluriomics will position Ncardia as a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modelling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia will provide tools to facilitate accelerated development of drugs, while replacing animal studies and putting a “human” aspect back into drug discovery.

According to Felix Haniel, VP Business Development & Sales of Ncardia: “Our vision is to develop products and services that are a complete solution. We will produce human iPSC derived cardiovascular and neuronal cell types and realize validated electrophysiology, biochemistry and contraction based assays. By combining over two decades of experience, Ncardia will offer iPSC assays for safety pharmacology, toxicology testing, drug efficacy screening, phenotypic screening, and disease modelling.”

Founded in 2001 as a spin-off of the University of Cologne, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. Now Axiogenesis specializes in human induced pluripotent stem cell products, including in vitro models of healthy and diseased cell types and tissues. In 2014, Axiogenesis founded its American subsidiary in Philadelphia, PA. [Read more…]

Filed Under: iPS Cells Tagged With: Axiogenesis, Ncardia, Pluriomics

Ncardia established following Pluriomics Axiogenesis merger

September 18, 2017 By Cade Hildreth (CEO) Leave a Comment

Ncardia, merger of Axiogenesis & Pluriomics

Builds foundation to become the trusted leader in hiPSC based drug discovery solutions.

Gosselies (BE), Cologne (DE), Leiden (NL), Philadelphia (USA), September 18th 2017 – Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings. [Read more…]

Filed Under: iPS Cells Tagged With: Axiogenesis, Ncardia, Pluriomics

Luxcel, Axiogenesis, and BMG LABTECH Secure €2.5M for Cell Metabolism Analysis Platform

February 15, 2017 By Cade Hildreth (CEO) 1 Comment

uxcel Axiogenesis BMG Labtech

Axiogenesis AGLuxcel Biosciences, Axiogenesis, and BMG LABTECH have announced €2.5M in funding to develop and launch a cell metabolism analysis platform, MetaCell™.

Together, these companies European technology subject matter experts (SMEs) have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot. The funding will support development of a cell metabolism analysis platform that aims to become integral to in vitro cell biology and drug development. [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: Axiogenesis, funding, Luxel Biosciences

Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service

February 1, 2017 By Cade Hildreth (CEO) Leave a Comment

contractile force of the heart | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service

contractility muscle | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay ServiceAxiogenesis, a worldwide leading provider of induced pluripotent stem cell (iPS cell) products, has added a vital new service offering: Cardio.Force, a technology for measuring the contractile force of the heart. This newest service offering includes assay services for iPSC-derived cardiomyocyte functionality and toxicity assessment.

In this article:

  1. The Cardio.Force Technology
  2. Cardio.Force’s Efficiency
  3. The Existing “Gold Standard” for Cardiac Force Assessment
  4. Cor.4CE Technology Overview
  5. Additional Advantages of the Cardio.Force Assay Service

Contractile Force of the Heart | Cardio.Force Service

The Cardio.Force Technology

Cardio.Force is based on the Axiogenesis’s 8-channel Cor.4CE assay device. Currently, 96 well versions are in development for an increased cardiac output and the reduction of cost per data point.

decreased contractility of heart | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service
(8 well measurement stage)

The utility of the technology was exemplified in a publication by Goßmann et al., “Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells.” In the study, Goßmann concludes, “The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data.”

Cardio.Force’s Efficiency

Such assay systems comprise the only cost-effective human in vitro technology that can measure the true cardiac contractile force of the heart. To date, common assay systems for quantitative measurement of contractility have been animal-based, which drive up cost and complexity. In contrast, the Cardio.Force assay offers an efficient system for pharmacological and toxicological studies using human cells that would otherwise require animal models or be more expensive/costly and with few cardiac outputs.

Cor.4U® human iPSC-derived cardiomyocytes are plated on extremely thin and highly flexible membranes for assessment of mechanobiological properties.

The Existing “Gold Standard” for Cardiac Force Assessment

Currently, the “Gold Standard” in toxicology and physiology has been isolated animal heart (Langendorff) preparations for contractility measurements. The Langendorff heart assay is a common in vitro approach used in pharmacological and physiological testing that allows cardiac contractile strength and heart rate to be determined without requiring an intact animal.[i]  The major disadvantages of this system are that it is still an animal model, is expensive, is costing $5-20K per compound, is technically challenging, and has relatively high variability.

Other emerging technologies using iPSC-derived cardiomyocytes require very high numbers of cells creating microtissues that make the technology very expensive, while the Cor.4CE system requires only 300K cells per sample measurement.

The Cor.4CE system is also reproducible and scalable, which gives it further cost advantages.

Secondary readouts that are being championed/currently pursued for analyzing and assessing cardiac contractility include impedance measurements, atomic force measurements, movement, and calcium flux analysis. These systems fail to consistently correlate with clinical data; in contrast, the Cor.4CE system does show the expected results including a positive frequency force relationship in reaction to beta-adrenergic stimulation (e.g., isoproterenol) can be observed, proving true force measurement.

Cor.4CE Technology Overview

The Axiogenesis’s Cor.4CE device involves the culture of validated human iPSC-derived cardiomyocytes (Cor.4U) on flexible membranes for a more physiological system. The Axiogenesis Cor.4CE Analysis software allows for derivation of the true contractile force of the heart from the measurement of the displacement of the membrane generated by the contracting cardiomyocytes. It allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical conditions. Optionally, Cor.4U cardiomyocytes can be co-cultured with Cor.4U fibroblasts in order to increase the physiological relevance of the cell system.

cardiac output normal | Axiogenesis Launches Cardio.Force, a Cardiac Contractile Force Assay Service
Example beat with assessed parameters

Additional Advantages of the Cardio.Force Assay Service

  • True force measurement in human iPSC-derived cardiomyocytes using proprietary Cor.4CE assay technology
  • Highly precise, standardized, and repeatable test system in defined/controlled culture conditions
  • Sensitive and predictive for cardiac safety pharmacology
  • Suitable for scale-up given low compound volumes, quick turnaround

In summary, the combination of Cor.4U with the Cor.4CE system is the first in vitro assay setup to measure the true contractile force of the heart of iPSC-derived cardiomyocytes in a system suitable for scale-up. The system provides an ideal tool to assess pharmacological, safety pharmacological, and toxicological effects of drug candidates on human cardiomyocytes.

 

If you found this article valuable, subscribe to BioInformant’s stem cell industry updates.

We are the industry leaders in stem cell research, with research cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, join more than half a million loyal readers, including physicians, scientists, investors, and philanthropists.

What is your opinion about the Cardio.Force technology of Axiogenesis? Share your thoughts in the comments section below.

Up Next: Cynata’s iPSC-derived Cell Therapeutic (CYP-001) Meets Safety & Efficacy Endpoints

 

Footnote

[i] Bell, R., Mocanu, M. & Yellon, D. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology 50, 940-950 (2011).

 

Editor’s Note: This post was originally published on February 1, 2017, and has been updated for quality and relevancy.

Filed Under: iPS Cells, Stem Cell News Tagged With: Axiogenesis, cardiac, product launch

Webinar: iPSC-derived Cell Models for Oncology Applications

January 7, 2017 By Cade Hildreth (CEO) 1 Comment

iPSC-derived Cell Models

Human cell models to assess cardiovascular and neurological safety liabilities of cancer drugs

Axiogenesis AG
Webinar Sponsored by Axiogenesis.

Early prediction of drug-induced toxicity is needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition.

Specifically, oncology drugs have become more effective in extending the lives of patients suffering from cancer. This improved prognosis, however, is giving more time for anti-cancer drugs to exert toxic effects such as cardiotoxicity, neuropathy and more. [Read more…]

Filed Under: iPS Cells Tagged With: Axiogenesis, iPSC, webinar

  • 1
  • 2
  • 3
  • 4
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.